These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 16813531

  • 1. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
    [Abstract] [Full Text] [Related]

  • 2. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 3. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 4. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT.
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [Abstract] [Full Text] [Related]

  • 5. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT.
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [Abstract] [Full Text] [Related]

  • 6. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P.
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [Abstract] [Full Text] [Related]

  • 7. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 8. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K.
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [Abstract] [Full Text] [Related]

  • 9. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG, Sod E, Johnson T, Chines A.
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.
    Menopause; 2008 Dec; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD.
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [Abstract] [Full Text] [Related]

  • 13. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD.
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [Abstract] [Full Text] [Related]

  • 16. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 17. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
    Heaney RP, Zizic TM, Fogelman I, Olszynski WP, Geusens P, Kasibhatla C, Alsayed N, Isaia G, Davie MW, Chesnut CH.
    Osteoporos Int; 2002 Apr; 13(6):501-5. PubMed ID: 12107665
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S.
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [Abstract] [Full Text] [Related]

  • 20. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.